Vogenx, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of treatments for serious diseases associated with dysfunctions in human metabolism. The company's primary clinical focus is on post-bariatric hypoglycemia (PBH) and gastroparesis. Its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule inhibitor of the sodium-glucose transporter 1 (SGLT1). Vogenx licensed the worldwide rights to mizagliflozin (excluding Japan, Korea, and Taiwan) from Kissei Pharmaceutical in 2021. In addition to its lead asset, the company's pipeline includes VGX-2857, a preclinical candidate being evaluated for weight maintenance and other metabolic indications, and VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes. As a pre-revenue, clinical-stage entity, Vogenx does not yet generate product sales and relies on equity financing, including its August 2026 initial public offering on the Nasdaq, to fund its ongoing research and clinical trials. The company operates out of its headquarters in Raleigh, North Carolina, and targets unmet medical needs in the metabolic and gastrointestinal therapeutic areas.
We couldn't find any ticker for VOGX. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!